CellCarta and Tivenix Strategic Partnership

Montreal, Canada & Lugano, Switzerland — July 21, 2025 – CellCarta, a global leader in precision medicine laboratory services, today announced a strategic partnership with Tivenix, a precision diagnostics company focused on neurodegenerative diseases. The two companies will collaborate to define and implement the clinical and regulatory strategy for the development and commercialization of Tivenix’s innovative diagnostic platform for Alzheimer’s Disease (AD) and other cell-death-related neurodegenerative conditions in Switzerland, North America and Europe. Both parties have agreed to keep the terms of the agreement confidential.

Tivenix’s diagnostic platform leverages advanced bioinformatics and whole genome sequencing to identify epigenetic biomarkers associated with neuronal death—a hallmark of neurodegenerative disorders such as Alzheimer’s. This novel approach aims to offer a highly sensitive, specific, and minimally invasive blood test to aid in early diagnosis and patient stratification in clinical trials.

“CellCarta is committed to enabling precision medicine by supporting the development of cutting-edge diagnostic technologies,” said Todd Chermak, SVP Immunology and Proteomics at CellCarta. “We are excited to support Tivenix’s mission to address the urgent need for better diagnostic tools in neurodegenerative diseases.”

“Partnering with CellCarta accelerates our clinical and regulatory path and gives us access to a world-class infrastructure for global deployment,” said Luca Soncini, Chairman of Tivenix. “Their scientific expertise and robust operational capabilities make them an ideal partner to support our strategic business growth and the clinical advancement of our cutting-edge diagnostic test.”

About CellCarta

CellCarta (www.cellcarta.com) is a global provider of precision medicine laboratory services, offering biomarker solutions by integrating analytical platforms in genomics, proteomics, immune monitoring, and histopathology. With a global footprint and a commitment to scientific excellence, CellCarta partners with biopharma companies to accelerate the development of transformative therapies.

About Tivenix

Tivenix (www.tivenix.com) is a Swiss digital company pioneering blood-based tests for neurodegenerative diseases. Its proprietary software platform analyzes epigenetic signals to detect neuronal death, offering a scalable and non-invasive tool for early diagnosis and patient stratification in Alzheimer’s Disease and beyond.